|ProteomeBinders at Alpbach, March 2007|
was established as a 4-year FP6 Research Infrastructures Coordination Action, starting in March 2006, funded with 1.8 M€ and linking 25 EU and 2 USA partners, leaders in the area of binders and their applications.
Affinity binding molecules, or ‘binders’, of which the most familiar are antibodies, are among the most essential reagents in biomedical research and an area where Europe has made breakthrough achievements. A major post-genome objective is to understand and exploit the proteome - the collection of proteins encoded by the genome and which carry out all cellular functions - including the expression, localisation, actions, interactions, modifications, and structure of all the proteins. Since defects in protein can lead directly to disease, a full understanding of the human proteome is of key importance for the future of healthcare and personalised medicine. One means to achieve proteome analysis is through the use of highly specific binders as probes, together with dedicated tools and methods for their use. This is known as affinity proteomics. In order to make this possible on a genome-wide scale, it is essential to create a comprehensive, standardised binder collection. The ProteomeBinders coordination action brings together leading European researchers in binder production (antibodies and alternative molecular types), as well as technologies and applications, to plan a comprehensive collection of binding molecules as a European research resource.
The objectives were achieved through a range of networking activities, covering resources, tools, applications, bioinformatics and databases, and forward planning. Although the project officially finished in May 2010, the ProteomeBinders consortium will remain a European and international voice advocating the establishment of a comprehensive infrastructure resource of binding molecules for detection of the human proteome,
together with tools for their use and applications in studying proteome function and organisation. Following on from the planning stage that ProteomeBinders was, two EC FP7 projects, AffinityProteome and AFFINOMICS are now running, carrying out large-scale binder generation.
For a quick overview of ProtemeBinders aims and achievements, download our brochure.
Dr. Michael Taussig, Babraham Bioscience Technologies, Cambridge CB22 3AT, UK
Dr. Oda Stoevesandt, Babraham Bioscience Technologies, Cambridge CB22 3AT, UK